FindTrial
Sign In

Minimally invasive esophagectomy

PROCEDURE6 trials

Sponsors

Chinese Academy of Medical Sciences, Shanghai Zhongshan Hospital, Austrian Society Of Surgical Oncology, National Taiwan University Hospital, University Medical Center Mainz

Conditions

Esophageal AdenocarcinomaEsophageal CancerEsophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0Time

Unknown Phase

Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy
NCT02448966
Chinese Academy of Medical SciencesEsophageal Cancer
Start: 2015-01-31End: 2019-12-31Target: 1000Updated: 2015-05-20
Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC
CompletedNCT03001596
Shanghai Zhongshan HospitalEsophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0
Start: 2017-01-31End: 2020-08-31Updated: 2020-09-10
Morbidity in Open Versus Minimally Invasive Esophagectomy
CompletedNCT03035071
Austrian Society Of Surgical OncologyEsophageal Cancer
Start: 2010-05-01End: 2016-04-18Updated: 2017-01-27
The Comparison of Single and Multi-incision MIE for Esophageal Cancer
NCT03646110
National Taiwan University HospitalEsophageal Cancer
Start: 2018-08-17End: 2021-07-26Target: 100Updated: 2020-11-05
RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
RecruitingNCT04306458
University Medical Center MainzEsophageal Adenocarcinoma
Start: 2021-01-18End: 2028-01-19Target: 218Updated: 2022-05-17
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
CompletedNCT06364566
Shanghai Zhongshan HospitalTime
Start: 2010-10-15End: 2019-10-15Updated: 2024-04-15

Related Papers

226. THE THERAPEUTIC EFFECTS OF NEO-ADJUVANT THERAPY ON LYMPH NODES METASTASIS FOR LOCALLY ADVANCED ESOPHAGEAL CANCER
Diseases of the Esophagus2025-08-01
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Journal for ImmunoTherapy of Cancer2023-02-0192 citations
Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial)
Journal of Thoracic Disease2023-02-017 citations
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
2022-11-15138 citations
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial).
2021-09-2667 citations
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
JAMA Surgery2021-03-17178 citations
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
2020-04-1512 citations
Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally invasive Esophagectomy).
2019-06-2132 citations
CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596)
BMC Cancer2017-06-2836 citations